undamentalytics Newsletter
Sign in

Hims & Hers Health, Inc. (HIMS) stock

Add to watchlist

Add holding +

NYSE: HIMS NYSE Health Care Services Next results ~November 9, 2026

C Fundamentals grade

Hims & Hers Health, Inc. is a US-listed company in the health care services industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Model estimate per share

~$9.9

Valuation models combined (4)

Base case. Range ~$6.8–$17. Weighted average of 4 models (growth cash-flow model, forward price-to-earnings vs peers, forward price-to-sales vs peers, revenue-to-maturity model), the growth cash-flow model counting double.

Price vs value

No Buy/Hold/Sell rating is issued: valued with our growth model, which doesn't carry a Buy/Hold/Sell rating yet.

Hims & Hers Health, Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders1 buying, 8 selling1 purchase and 46 sales by directors and officers, last 12 monthsInsider trades
  • Funds314 adding, 194 cuttingOf 50 active managers that changed their stake, 30 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Hims & Hers Health files

Where Hims & Hers Health stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $2.58bn, up 28.0% on a year earlier, slower than the 32.8% growth a quarter earlier. That growth ranks 4 of 21 among the health care services companies we cover. Free-cash-flow margin fell to 2.4% from 5.9% a year earlier. Operating margin narrowed to -6.0% from 6.2%. Against its peers on growth, profitability, cash generation and balance sheet, it grades C. It passes 0 of our 2 financial-health checks. Our revenue-to-maturity cash-flow model value is $12.47 a share, against a share price of $27.56.

Source: 10-Q filed August 10, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 9, 2026 (estimated)

Hims & Hers Health, Inc.'s trailing-twelve-month revenue grew 28.0% year on year, with a free-cash-flow margin of 2.4%. Where it stands out: days sales outstanding of 5 days ranks 2 of 31 health care services companies we cover. Where it lags: change in growth rate of -4.8pp ranks 37 of 41 health care services companies we cover.

Current signal Balance sheet growing far ahead of sales: Total assets grew 93% year over year while revenue grew 28% — the balance sheet is expanding 65 points faster than the business it supports.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Fast growth. Revenue grew 28.0% over the last 12 months, against a median of 7.3% for health care services companies we cover.
  • Net cash. Cash exceeds long-term debt by $0.6bn.

Things to watch

  • Loss-making. Operating margin is -6.0%: costs exceed revenue.
  • Margins narrowing. Operating margin is down 12.2 points on a year ago.
  • Volatile shares. Over the past year the shares showed annualised volatility of 89% and a beta of 2.8 against the S&P 500.
  • Growth easing. The growth rate is 4.8 points lower than a quarter earlier.
  • Gross margin slipping. Gross margin is down 7.8 points on a year ago.
  • Below peers: change in growth rate. Change in growth rate of -4.8pp ranks 37 of 41 health care services companies we cover (median +1.1pp).

Latest results: FY2026 Q2

Filed August 10, 2026
Earnings per share
-$0.37 against an average estimate of -$0.05: missed by 640.0%
Revenue
$753m, up 38.2% on a year earlier
Share reaction
-3.4% in the first session after the results on August 10, 2026, against -0.3% for the S&P 500
Guidance given
revenue $880m to $900m (third quarter 2026); adjusted EBITDA $75m to $95m (third quarter 2026)
Next report
November 9, 2026; average EPS estimate $0.15

Hims & Hers Health's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-8.8%
  • 1 week-8.5%
  • 1 month-13.0%
  • This year-22.3%
  • 1 year-44.5%
  • 5 years+205.6%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$2.6B
Operating margin
-6.0%
Net margin
-5.5%
EPS (TTM, diluted)
$-0.57

Growth

Revenue growth
+28.0%
Change in growth rate
−4.8 pts
Share count change
+0.3%

Cash

Free cash flow (TTM)
$61.5M
FCF margin
2.4%
Stock pay % of revenue
6.0%

Earnings

Last results
August 10, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Product
  2. Results
  3. Product
  4. Leadership
  5. Leadership
  6. Announcement
  7. Announcement
  8. Results
  9. Guidance
  10. Announcement
  11. Leadership

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Hims & Hers Health, Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: valued with our growth model, which doesn't carry a Buy/Hold/Sell rating yet.

Valuation models

We value Hims & Hers Health, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 11.2%: the 10-year Treasury yield (4.9%) plus a beta of 1.39 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Growth cash-flow model Revenue for this year and next from analysts' consensus, then growth fading to 2.5%; the operating margin moving to profitable peers'; investment needed per dollar of growth from peers; reduced by a failure probability. For young or fast-growing companies. The starting margin is normalized to between -100% and 60%; net margin is a proxy when operating income is not tagged. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$6.8 ~$2.8–$10 Primary model, counts double
Forward price-to-earnings vs peers Next year's consensus earnings per share times peers' typical (harmonic-mean) forward price-to-earnings. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$7.5 ~$6.1–$11 Included
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. ~$0.0 Left out: out of range vs price (0.00x)
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: return on equity is not positive
Forward price-to-sales vs peers Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$13 ~$13–$38 Included, half weight
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. ~$17 ~$13–$21 Included
Combined value Weighted average of the models that apply: the primary model (growth cash-flow model) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$9.9 ~$6.8–$17 4 models

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Hims & Hers Health, Inc. with Health Care Services in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 2019202020212022202320242025Now
Share price$9.90$14.60$6.55$6.41$8.90$24.18$32.47$25.24
Market value$1.7bn$2.6bn$1.2bn$1.3bn$1.9bn$5.7bn$8.4bn$6.2bn
+ Net debt (− = net cash)−$2m−$27m−$72m−$47m−$97m−$221m$744m$755m
Enterprise value$1.7bn$2.6bn$1.2bn$1.3bn$1.8bn$5.5bn$9.1bn$7.0bn
Multiples
Price / sales 20.8x17.3x4.5x2.5x2.1x3.9x3.6x2.4x
Price / earnings —————45.4x65.3x—
Price / free cash flow ————39.7x28.9x146.1x101.5x
EV / EBITDA —————69.7x57.0x—

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

33 /100

Weak moat

How hard Hims & Hers Health's competitive advantage looks for rivals to wear away, judged from 7 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Net income has been a median -3.9% of total assets over 7 years.

  • Pricing power 18 / 20

    Gross margin has been a median 76.6%, moving by 4.4 percentage points (standard deviation) across 6 years.

  • Durability 10 / 20

    Operating margin has been a median -6.7%; its worst year was -37.7%.

  • Discipline 3 / 20

    The diluted share count rose 137.6% over five years; stock-based pay has been a median 7.5% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (38 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 9, 2026, after the close. Analysts expect revenue of $893m and EPS of $0.15 (range −$0.05 to $0.35) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$0.56 −210% $3.2bn +37%
Next $0.42 +175% $4.0bn +25%

Next year's EPS estimate has moved −32.0% in 90 days, across 11 analysts.

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.05 −$0.37 −640.0%
Mar 2026 $0.03 −$0.40 −1664.3%
Dec 2025 $0.04 $0.08 +92.5%
Sept 2025 $0.10 $0.06 −41.0%

Adjusted EPS as companies report it, against the average analyst estimate.

Management guidance

Earnings release, August 10, 2026
  • Revenue full year 2026 $3.1bn to $3.3bn Raised
    “Revenue of $3.1 billion to $3.3 billion.” source
  • Revenue third quarter 2026 $880m to $900m
    “Revenue of $880 million to $900 million.” source
  • Adjusted EBITDA full year 2026 $275m to $325m Non-GAAP
    “Adjusted EBITDA of $275 million to $325 million, reflecting an Adjusted EBITDA margin of 9% to 10%.” source
  • Adjusted EBITDA margin full year 2026 9% to 10% Non-GAAP
    “Adjusted EBITDA of $275 million to $325 million, reflecting an Adjusted EBITDA margin of 9% to 10%.” source
  • Adjusted EBITDA third quarter 2026 $75m to $95m Non-GAAP
    “Adjusted EBITDA of $75 million to $95 million, reflecting an Adjusted EBITDA margin of 9% to 11%.” source
  • Adjusted EBITDA margin third quarter 2026 9% to 11% Non-GAAP
    “Adjusted EBITDA of $75 million to $95 million, reflecting an Adjusted EBITDA margin of 9% to 11%.” source

Figures and quotations are management's, copied from the company's own press release (SEC 8-K exhibit) and checked word for word against it. Forward-looking statements are the company's expectations, not ours and not advice; guidance can change or be missed.

Analyst recommendations

15 analysts, Oct 2026
Buy320%
Hold1280%
Sell00%

Monthly trend

  1. Oct 202621215
  2. Sep 202621115
  3. Aug 202621115
  4. Jul 202621215

Counts of recommendations published by analysts covering Hims & Hers Health, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
28.2%
of tradable shares
Days to cover
5.76
at average volume
Short interest, 1 month
−0%
to September 30, 2026
Held by institutions
71%
of shares
Held by insiders
4.9%
of shares
Employees
2,442
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months −44.5%

$45.46 on October 31, 2025 to $25.24

ThenNowEffect
Revenue (last 12 months) $2.0bn $2.6bn +28.0%
P/S multiple 5.6x 2.4x −56.5%
Share count 247m 247m −0.3%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

Last 3 years +289.5%

$6.48 on November 3, 2023 to $25.24

ThenNowEffect
Revenue (last 12 months) $711m $2.6bn +262.7%
P/S multiple 1.9x 2.4x +28.5%
Share count 207m 247m −16.4%

Biggest factor: revenue. Loss-making at one end, so the split uses price/sales.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
HIMS−55%−2%+39%+172%+34%−22%
Industry peers (median)−1%−28%+6%−6%−9%+15%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
HIMS25%58%50%67%50%46%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
HIMS−78%−54%−52%−45%−63%−59%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since September 13, 2019: 87% from February 8, 2021 to May 11, 2022. Getting back needed a 687% gain, reached on June 18, 2024, 769 days after the low.

Price behaviour

52-week range
$14.52 – $44.39
From 52-week high
−43.1%
vs 50-day average
−12.6%
vs 200-day average
−6.5%
Volatility (1 year)
89%
Beta vs S&P 500
2.83

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
5 up, 7 down
typical move ±11.4%
After a week
6 up, 6 down
typical move ±20.1%
After a month
6 up, 6 down
typical move ±36.1%
Results releasedNext dayS&P 500 next day5 days21 days
August 10, 2026 −3.4% −0.3% −9.4% −11.7%
May 11, 2026 −11.5% +0.1% −21.2% −1.7%
February 23, 2026 −1.1% −0.3% +5.4% +36.5%
November 3, 2025 −5.9% −1.0% −9.7% −18.5%
August 4, 2025 −11.2% +1.0% −20.1% −28.9%
May 5, 2025 +21.2% −1.4% +35.3% +31.3%
February 24, 2025 −19.1% −1.0% −17.5% −24.8%
November 4, 2024 +1.4% +1.0% +36.9% +66.6%
August 5, 2024 −4.0% −2.0% −9.2% −16.9%
May 6, 2024 +9.7% +1.1% +14.5% +93.2%
February 26, 2024 +41.1% −0.2% +54.4% +66.2%
November 6, 2023 +7.6% +0.5% +8.0% +37.3%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Hims & Hers Health, Inc. in five measures

Fundamentals grade C
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Hims & Hers Health, Inc.
$0 $1B $2B $3B FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $792.6M Revenue (TTM), FY23 Q4: $872M Revenue (TTM), FY24 Q1: $959.4M Revenue (TTM), FY24 Q2: $1.1B Revenue (TTM), FY24 Q3: $1.2B Revenue (TTM), FY24 Q4: $1.5B Revenue (TTM), FY25 Q1: $1.8B Revenue (TTM), FY25 Q2: $2B Revenue (TTM), FY25 Q3: $2.2B Revenue (TTM), FY25 Q4: $2.3B Revenue (TTM), FY26 Q1: $2.4B Revenue (TTM), FY26 Q2: $2.6B $2.6B

Source: SEC EDGAR filings. Retrieved October 26, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $792.6M
FY23 Q4 $872M
FY24 Q1 $959.4M
FY24 Q2 $1.1B
FY24 Q3 $1.2B
FY24 Q4 $1.5B
FY25 Q1 $1.8B
FY25 Q2 $2B
FY25 Q3 $2.2B
FY25 Q4 $2.3B
FY26 Q1 $2.4B
FY26 Q2 $2.6B
Revenue growth, TTM YoY Hims & Hers Health, Inc.
0% 50% 100% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue growth, TTM YoY, FY23 Q3: 78.3% Revenue growth, TTM YoY, FY23 Q4: 65.5% Revenue growth, TTM YoY, FY24 Q1: 55.7% Revenue growth, TTM YoY, FY24 Q2: 50.1% Revenue growth, TTM YoY, FY24 Q3: 56.7% Revenue growth, TTM YoY, FY24 Q4: 69.3% Revenue growth, TTM YoY, FY25 Q1: 86.0% Revenue growth, TTM YoY, FY25 Q2: 88.7% Revenue growth, TTM YoY, FY25 Q3: 78.0% Revenue growth, TTM YoY, FY25 Q4: 59.0% Revenue growth, TTM YoY, FY26 Q1: 32.8% Revenue growth, TTM YoY, FY26 Q2: 28.0% 28.0%

Source: SEC EDGAR filings. Retrieved October 26, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q3 78.3%
FY23 Q4 65.5%
FY24 Q1 55.7%
FY24 Q2 50.1%
FY24 Q3 56.7%
FY24 Q4 69.3%
FY25 Q1 86.0%
FY25 Q2 88.7%
FY25 Q3 78.0%
FY25 Q4 59.0%
FY26 Q1 32.8%
FY26 Q2 28.0%
Operating margin (TTM) Hims & Hers Health, Inc.
-10% -5% 0% 5% 10% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Operating margin (TTM), FY23 Q3: -5.1% Operating margin (TTM), FY23 Q4: -3.4% Operating margin (TTM), FY24 Q1: -0.9% Operating margin (TTM), FY24 Q2: 1.1% Operating margin (TTM), FY24 Q3: 3.5% Operating margin (TTM), FY24 Q4: 4.2% Operating margin (TTM), FY25 Q1: 6.2% Operating margin (TTM), FY25 Q2: 6.2% Operating margin (TTM), FY25 Q3: 5.2% Operating margin (TTM), FY25 Q4: 4.5% Operating margin (TTM), FY26 Q1: -1.3% Operating margin (TTM), FY26 Q2: -6.0% -6.0%

Source: SEC EDGAR filings. Retrieved October 26, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q3 -5.1%
FY23 Q4 -3.4%
FY24 Q1 -0.9%
FY24 Q2 1.1%
FY24 Q3 3.5%
FY24 Q4 4.2%
FY25 Q1 6.2%
FY25 Q2 6.2%
FY25 Q3 5.2%
FY25 Q4 4.5%
FY26 Q1 -1.3%
FY26 Q2 -6.0%
FCF margin (TTM) Hims & Hers Health, Inc.
0% 5% 10% 15% FY24 Q4 FY25 Q2 FY25 Q4 FY26 Q2 FCF margin (TTM), FY24 Q4: 13.4% FCF margin (TTM), FY25 Q1: 13.3% FCF margin (TTM), FY25 Q2: 5.9% FCF margin (TTM), FY25 Q3: 5.4% FCF margin (TTM), FY25 Q4: 2.4% FCF margin (TTM), FY26 Q1: 2.5% FCF margin (TTM), FY26 Q2: 2.4% 2.4%

Source: SEC EDGAR filings. Retrieved October 26, 2026.

View chart data
Period FCF margin (TTM)
FY24 Q4 13.4%
FY25 Q1 13.3%
FY25 Q2 5.9%
FY25 Q3 5.4%
FY25 Q4 2.4%
FY26 Q1 2.5%
FY26 Q2 2.4%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Where the money goes

FY2025, from the 10-K

Each dollar Hims & Hers Health took in during FY2025, followed through to profit: what it cost to make, what went on running the business, and what was left after tax.

  1. Revenue $2.3B
  2. Other income $22.8M · 1.0%
  3. Cost of revenue $614M · 26.2%
  4. Gross profit $1.7B · 73.8%
  5. Selling, general and admin $273M · 11.6%
  6. Other operating costs $1.4B · 57.7%
  7. Operating income $106M · 4.5%
  8. Net income $128M · 5.5%

Shares of revenue. Source: Hims & Hers Health's 10-K for FY2025, as filed with the SEC. "Other" lines are what the reported lines leave unexplained. Other income is income outside operations, such as investment gains.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 83 149 272 527 872 1,477 2,348 2,578
Gross profit 45 109 204 409 715 1,173 1,733 1,764
EBITDA −74 −14 −111 −61 −20 79 160 −67
Operating income −74 −15 −115 −69 −29 62 106 −155
Net income −72 −18 −108 −66 −24 126 128 −142
Diluted EPS −$0.41 −$0.10 −$0.58 −$0.32 −$0.11 $0.53 $0.51 −$0.57
Growth (year on year)
Revenue — +80.2% +82.8% +93.8% +65.5% +69.3% +59.0% +28.0%
EBITDA — — — — — — +102.7% −143.5%
Operating income — — — — — — +70.6% −223.0%
Net income — — — — — — +1.8% −173.4%
Diluted EPS — — — — — — −3.8% −173.1%
Margins
Gross margin 54.0% 73.6% 75.2% 77.6% 82.0% 79.5% 73.8% 68.4%
EBITDA margin −89.8% −9.5% −40.8% −11.6% −2.3% 5.3% 6.8% −2.6%
Operating margin −90.1% −10.2% −42.3% −13.0% −3.4% 4.2% 4.5% −6.0%
Net margin −87.3% −12.2% −39.6% −12.5% −2.7% 8.5% 5.5% −5.5%
Free-cash-flow margin — — — −6.4% 5.4% 13.4% 2.4% 2.4%
Cash flow
Cash from operations −75 −2 −34 −27 73 251 300 263
Capital spending — — — 7 27 53 243 202
Free cash flow — — — −34 47 198 57 62
Stock-based pay 8 6 67 43 66 92 135 154
Free cash flow after stock pay — — — −77 −19 106 −78 −92
Balance sheet
Cash 2 27 72 47 97 221 229 610
Total debt 0 0 0 0 0 0 973 1,365
Net debt (negative = net cash) −2 −27 −72 −47 −97 −221 744 755
Diluted shares 174m 177m 187m 205m 209m 237m 258m 247m
Returned to shareholders
Buybacks 0 0 0 0 2 83 90 —
Total returned 0 0 0 0 2 83 90 —

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

0 of 2 checks passed · June 30, 2026
What it owns · $3.6bn
Short-term assets $1.4bnLonger-term assets $2.2bn
What it owes, and who funded it · $3.6bn
Short-term liabilities $1.5bnLonger-term liabilities $1.8bnShareholders' equity $324m
  • Short-term assets cover short-term liabilities $1.4bn of assets due within a year against $1.5bn of liabilities due within a year.
  • Short-term assets cover long-term liabilities $1.4bn short-term assets against $1.8bn of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From Hims & Hers Health, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

FY2025 Q4 TTM
Buybacks (TTM)
$90M
Returned to shareholders
157%
of free cash flow
Buybacks, last 3 fiscal years
$175M
Diluted share count
+0.3%
year over year
Total shareholder yield
1.5%
dividends 0.0% + buybacks 1.5% of market value
Days sales outstanding
5 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in health care services
Last 12 months unless stated HIMS AVAH CHE PRVA RDNT EVH Median
Revenue, last 12 months $2.6bn $2.6bn $2.7bn $2.4bn $2.3bn $2.1bn $1.2bn
Revenue growth, last 12 months 28.0% 19.5% 5.2% 24.1% 18.9% −4.5% 7.3%
Revenue growth, 3-year average 53.7% 12.4% 6.1% 16.1% 14.1% 8.7% 11.3%
Revenue growth, latest quarter 38.2% 13.7% 10.6% 21.4% 25.0% 46.9% 8.5%
Gross margin 68.4% 32.3% 33.5% — 13.4% 17.2% 27.9%
Operating margin −6.0% 10.5% 13.9% 1.9% 3.1% −20.4% 2.3%
Operating margin, 3-year average 0.5% 7.0% 14.4% 1.2% 4.4% −8.0% 2.3%
Net margin −5.5% 10.6% 10.6% 1.2% −0.9% −24.1% 1.2%
Cash from operations / revenue 10.2% 6.5% 13.6% 5.6% 13.7% 2.6% 6.1%
Free-cash-flow margin 2.4% 6.0% 11.1% 5.6% 3.2% −2.7% 5.1%
Free-cash-flow margin, 3-year average — 3.2% 11.6% 5.2% 3.7% −2.3% 3.6%
Stock pay / revenue 6.0% 0.7% — 3.2% 2.6% 2.0% 1.1%
Change in share count 0.3% 11.4% −8.3% 2.7% 0.1% −2.4% 0.3%

Median of all 41 companies we cover in health care services. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

41 health care services companies
Measure Company Peer median Rank
Revenue growth Growth 28.0% 7.3% 8 of 41
Change in growth rate Growth -4.8pp +1.1pp 37 of 41
Gross margin Profitability 68.4% 29.0% 4 of 27
Operating margin Profitability -6.0% 2.6% 29 of 40
Net margin Profitability -5.5% 1.2% 27 of 41
Free-cash-flow margin Cash generation 2.4% 5.1% 27 of 40
Stock pay as % of revenue Cash generation 6.0% 0.9% 29 of 35
Change in share count Balance sheet 0.3% 0.4% 19 of 39
Days sales outstanding Balance sheet 5 days 39 days 2 of 31

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to December 31, 2025
Geography
Region Revenue Share YoY
United States $2.2B 94.3% ▲ 52.7%
Outside the US $134M 5.7% ▲ 399.2%

From Hims & Hers Health, Inc.'s 10-K filed February 23, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$5.4B
Institutions reporting
505
Shares held vs prior quarter
▲ 4.8%
Positions opened / closed
136 / 64

Top buyers and sellers, Q2 2026: 314 institutions bought and 194 sold ; the biggest buyer was Divisadero Street Capital Management, LP (+5.5M shares) and the biggest seller Defiance Etfs, LLC (−7.4M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Blackrock, Inc. $995M 28.7M 18.4% ▲ 9.0%
Vanguard Portfolio Management LLC $366M 10.6M 6.8% ▲ 3.7%
Vanguard Capital Management LLC $331M 9.5M 6.1% ▲ 2.2%
State Street Corp $282M 8.1M 5.2% ▲ 9.2%
Morgan Stanley $248M 7.2M 4.6% ▼ 19.5%
Divisadero Street Capital Management, LP $208M 6.0M 3.9% ▲ 1179.1%
Geode Capital Management, LLC $197M 5.7M 3.6% ▲ 9.3%
Goldman Sachs Group Inc $179M 5.2M 3.3% ▲ 110.8%
Jpmorgan Chase & Co $159M 4.8M 2.9% ▼ 9.0%
FMR LLC $150M 4.3M 2.8% ▲ 4535.2%
Marshall Wace, LLP $146M 4.2M 2.7% ▲ 482.4%
UBS Group AG $92.3M 2.7M 1.7% ▼ 35.9%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Hims & Hers Health, Inc.'s complete shareholder register. Values are as reported by the filers ; 3 inconsistently scaled filing rows were excluded.

Insider trading activity

Full insider history and chart
Insider purchases History → $1.2M 1 trade by 1 insider, last 12 months Insider sales History → $19.4M 46 trades by 8 insiders · 100% under pre-set plans
Net ▼ $18.2M net selling
Insider Date Trade Shares Price Value
Boughton Soleil Chief Legal Officer October 28, 2026 Sell pre-set plan 3,462 $27.60 $95,551
Boughton Soleil Chief Legal Officer October 14, 2026 Sell pre-set plan 3,461 $29.06 $100,577
Okupe Oluyemi Chief Financial Officer October 1, 2026 Sell pre-set plan 2,000 $29.70 $59,400
Boughton Soleil Chief Legal Officer September 30, 2026 Sell pre-set plan 3,461 $29.17 $100,957
Okupe Oluyemi Chief Financial Officer September 22, 2026 Sell pre-set plan 29,277 $29.95 $876,846
Okupe Oluyemi Chief Financial Officer September 17, 2026 Sell pre-set plan 12,313 $28.82 $354,861
Boughton Soleil Chief Legal Officer September 16, 2026 Sell pre-set plan 6,236 $27.86 $173,735
Elshenawy Mohamed CTO September 15, 2026 Sell pre-set plan 7,954 $28.39 $225,814
Chi Michael Chief Operating Officer September 15, 2026 Sell pre-set plan 14,027 $28.39 $398,227
Boughton Soleil Chief Legal Officer September 2, 2026 Sell pre-set plan 3,458 $28.33 $97,965
Boughton Soleil Chief Legal Officer August 19, 2026 Sell pre-set plan 25,111 $27.55 $691,808
Okupe Oluyemi Chief Financial Officer August 19, 2026 Sell pre-set plan 4,938 $29.99 $148,091

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Trades by members of Congress

All 1 trade and filings

No trades in Hims & Hers Health, Inc. disclosed in the last 12 months; 1 earlier trade on record.

  • Lisa C. McClain(R-MI 9):Purchase, $1,001 - $15,000, traded August 4, 2025, filed September 12, 2025

Value ranges as filed; reports can arrive up to 45 days after a trade.

Earnings dates and SEC filings

Results announcements

Next expected around November 2, 2026 estimated from the company's past filing pattern, not announced

  • August 10, 2026
  • May 11, 2026
  • February 23, 2026
  • November 3, 2025
  • August 4, 2025
  • May 5, 2025

Recent SEC filings

Data status

When each part of this page on Hims & Hers Health, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Hims & Hers Health, Inc. in brief

What does Hims & Hers Health, Inc. do?
Hims & Hers Health, Inc. is a US-listed company in the health care services industry. Its financial year ends in December.
What is Hims & Hers Health, Inc.'s stock ticker?
Hims & Hers Health, Inc. trades under the ticker HIMS on NYSE. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Hims & Hers Health, Inc.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Hims & Hers Health, Inc. reported revenue of $2.6B, 28.0% higher than a year earlier, according to its SEC filings.
What is Hims & Hers Health, Inc.'s free cash flow?
Hims & Hers Health, Inc.'s free-cash-flow margin is 2.4% of revenue over the trailing twelve months, ranking 27 of the 40 health care services companies we cover.
Who are Hims & Hers Health, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Blackrock, Inc., Vanguard Portfolio Management LLC and Vanguard Capital Management LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
Is Hims & Hers Health, Inc. buying back stock, and does it pay a dividend?
Hims & Hers Health, Inc. spent $90M on share repurchases over the trailing twelve months, and its diluted share count still rose 0.3% over the year.
What is Hims & Hers Health, Inc.'s market cap?
On November 2, 2026, Hims & Hers Health, Inc.'s market capitalisation was about $6.2B and net debt of $755M. Market figures come from third-party market data and may be delayed.
Who are Hims & Hers Health, Inc.'s competitors?
In our Health Care Services peer group, the companies closest to Hims & Hers Health, Inc. are Aveanna Healthcare Holdings, Inc., Chemed Corp, Privia Health Group, Inc., Radnet, Inc. and Evolent Health, Inc. The side-by-side comparison below sets their revenue, margins and growth against Hims & Hers Health, Inc.'s.
Are insiders buying or selling Hims & Hers Health, Inc. stock?
Over the last 12 months, Hims & Hers Health, Inc.'s directors and officers reported 1 open-market purchases and 46 sales on Form 4. The insider trading page charts every trade.
When is Hims & Hers Health, Inc.'s next earnings date?
Around November 9, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Hims & Hers Health, Inc. announces its own schedule.